Working… Menu

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01676259
Recruitment Status : Unknown
Verified September 2018 by Silenseed Ltd.
Recruitment status was:  Recruiting
First Posted : August 30, 2012
Last Update Posted : March 12, 2019
Information provided by (Responsible Party):
Silenseed Ltd

Brief Summary:

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment.

Primary Outcome:

- Progression-free survival (PFS) in the study population.

Condition or disease Intervention/treatment Phase
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Drug: siG12D-LODER Drug: Gemcitabine+nab-Paclitaxel Phase 2

Detailed Description:

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable LAPC combined with chemotherapy treatment (Gemcitabine+nab-Paclitaxel). This will be the first study to assess the response rate of the siG12D-LODER in patients with unresectable LAPC. The study is of a two-arm design with one arm receiving siG12D-LODER + chemotherapy, and the other arm receiving only chemotherapy.

The investigational agent siG12D-LODER is a miniature biodegradable bio polymeric matrix that encompasses the drug, designed and produced by Silenseed Ltd. The implantation of LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.

siG12D-LODER has been studied in the escalating dose Phase I study of 15 patients, and results showed high safety and tolerability profiles, with no single DLT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone
Actual Study Start Date : March 7, 2018
Estimated Primary Completion Date : November 2019
Estimated Study Completion Date : June 2020

Arm Intervention/treatment
Active Comparator: Chemotherapy
Drug: Gemcitabine+nab-Paclitaxel
Other Name: Chemotherapy

Experimental: siG12D-LODER + chemotherapy
Eight siG12D-LODER+(Gemcitabine+nab-Paclitaxel)
Drug: siG12D-LODER
The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.

Drug: Gemcitabine+nab-Paclitaxel
Other Name: Chemotherapy

Primary Outcome Measures :
  1. Progression-free survival (PFS) in the study population [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who provide written informed consent to participate in the study
  • Men and women patients 18 years of age and up
  • Have an unresectable, locally advanced pancreatic cancer (AJCC stage III). (Excluded: resectable and borderline resectable patients are ineligible per NCCN criteria)
  • Allocated to receive Gemcitabine + nab-Paclitaxel as first line treatment.
  • Have a target tumor that is accessible for intratumoral administration by EUS (Endoscopic Ultrasound) guidance as determined by the radiologist/gastroenterologist performing the EUS insertion.
  • Have an ECOG performance status of ≤ 1
  • If female and of childbearing potential, have a negative serum or urine pregnancy test during screening. Agree to use a barrier method of contraception if sexually active (both men and women) from the time of administration of the first treatment and for at least 8 weeks after treatment.
  • Have serum creatinine <1.6 mg/dL, INR < 1.5 U, absolute neutrophil count (ANC) > 1.5 x 109/L , platelets ≥ 100 x 109/L , hemoglobin ≥ 9 mg/dL, ALT and AST ≤ 5 x ULN, bilirubin ≤ 1.5 x ULN
  • Have measurable disease. Patients must have clinically and/or radiographically documented measurable primary disease according to RECIST 1.1. At least one site of disease must be unidimensionally measurable. All radiology scans must be performed within 28 days prior to registration

Exclusion Criteria:

  • Subjects with resectable and borderline resectable pancreatic cancer
  • Evidence of metastatic disease
  • Other malignancy that would interfere with the current intervention
  • Any evidence of ascites (beyond trace)
  • Bulky celiac adenopathy (≥2.5 cm) or nonadenocarcinoma histology.
  • Any prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational).
  • Prior therapy with any hypoxic cytotoxin (hypoxia-targeting drugs).
  • Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers from which the subject has been disease-free for at least 2 years
  • Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation <90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
  • History of clinically significant coagulopathy
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
  • New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 4months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Subjects who participated in an investigational drug or device study within 28 days prior to study entry
  • Known active infection with HIV, hepatitis B virus, or hepatitis C virus
  • Females who are pregnant or breast-feeding
  • Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • Unwillingness or inability to comply with the study protocol for any reason
  • Known allergy to sesame oil

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01676259

Layout table for location contacts
Contact: Orit Pollack-Shragai, MSc, MBA +972-52-8466267

Layout table for location information
United States, New Jersey
Hackensack Meridian Health Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Chelsea McCabe    551-996-5863   
Contact: Laura Esposito    +1 551-996-5863   
Principal Investigator: Martin Gutierrez, MD         
Principal Investigator: Rosario Ligresti, MD         
United States, New York
The Mount Sinai Hospital Recruiting
New York, New York, United States, 10029
Contact: Celina Ang, MD    212-824-8551   
Contact: Christopher DiMaio, MD    212-241-7531   
Principal Investigator: Celina Ang, MD         
Principal Investigator: Christopher J DiMaio, MD         
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Eileen M O'Reilly, MD    646-888-4182   
Contact: Anna M Varghese, MD    646-888-4308   
Principal Investigator: Eileen M. O'Reilly, MD         
Principal Investigator: Anna M Varghese, MD         
Principal Investigator: Mark A Schattner, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Milind Javle, MD    713-792-5434   
Contact: Manoop Bhutani, MD    1-713-792-2121   
Principal Investigator: Milind Javle, MD         
Principal Investigator: Manoop Bhutani, MD         
Rambam Medical Center Recruiting
Haifa, Israel, 3525408
Contact: Valerya Semenysty, MD    +972-4-7776419   
Contact: Iyad Khamaysi, MD    +972-4-7773626   
Principal Investigator: Valerya Semenysty, MD         
Sub-Investigator: Iyad Khamaysi, MD         
Rabin Medical Center Recruiting
Petah Tikva, Israel, 49102
Contact: Salomon M Stemmer, MD    +972-3-9378005   
Contact: Ala Malcham, MD    +972- 3-9377241   
Principal Investigator: Salomon M Stemmer, MD         
Sub-Investigator: Alaa Melhem, MD         
Sheba Medical Center (Tel H'shomer) Recruiting
Ramat Gan, Israel, 52621
Contact: Talia Golan, MD    +972-3-5305338   
Contact: Maor Lahav, MD    +972- 3-5305875   
Principal Investigator: Talia Golan, MD         
Sub-Investigator: Maor Lahav, MD         
Assaf Harofeh Medical Center Recruiting
Tzrifin, Israel, 70300
Contact: Nirit Yarom, MD    972-8-9778144   
Contact: Shai Matalon, MD    972-527360731   
Principal Investigator: Nirit Yarom, MD         
Sub-Investigator: Shai Matalon, MD         
Sponsors and Collaborators
Silenseed Ltd
Layout table for investigator information
Principal Investigator: Eileen M O'Reilly, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Talia Golan, MD Sheba Medical Center
Additional Information:
Layout table for additonal information
Responsible Party: Silenseed Ltd Identifier: NCT01676259    
Other Study ID Numbers: SLSG12D-P2
First Posted: August 30, 2012    Key Record Dates
Last Update Posted: March 12, 2019
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Silenseed Ltd:
RNA interference (RNAi)
Pancreatic ductal adenocarcinoma
Locally Advanced Pancreatic cancer
Solid tumor
Non operable pancreatic ductal adenocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs